bioAffinity Technologies, Inc. (NASDAQ:BIAF) Sees Large Decline in Short Interest

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the target of a large drop in short interest in February. As of February 28th, there was short interest totalling 115,500 shares, a drop of 54.1% from the February 13th total of 251,900 shares. Based on an average trading volume of 189,000 shares, the short-interest ratio is presently 0.6 days. Approximately 1.2% of the shares of the company are short sold.

bioAffinity Technologies Stock Up 3.6 %

Shares of BIAF stock opened at $0.37 on Friday. The stock’s 50 day simple moving average is $0.68 and its 200 day simple moving average is $1.16. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.01 and a current ratio of 1.02. bioAffinity Technologies has a twelve month low of $0.26 and a twelve month high of $3.16. The company has a market capitalization of $5.72 million, a price-to-earnings ratio of -0.45 and a beta of 3.13.

Institutional Inflows and Outflows

An institutional investor recently raised its position in bioAffinity Technologies stock. Sheaff Brock Investment Advisors LLC lifted its stake in bioAffinity Technologies, Inc. (NASDAQ:BIAF) by 131.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 46,304 shares of the company’s stock after acquiring an additional 26,304 shares during the period. Sheaff Brock Investment Advisors LLC owned 0.30% of bioAffinity Technologies worth $42,000 at the end of the most recent reporting period. 1.64% of the stock is currently owned by institutional investors.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.